Shengjia (Binhai) Biomedical Technology Co., Ltd.

Main purpose of study: According to the relevant provisions of bioequivalence test, Boehringer Ingelheim International GmbH was selected as the licensee, and Telmisartan Amlodipine Tablets (trade name: Twynsta®, specification: 80mg/5mg) provided by Tianjin Palm Pharmaceutical Technology Co., Ltd. was selected as the reference preparation. The human bioequivalence test of the test preparation Telmisartan Amlodipine Tablets (specification: 80mg/5mg) produced and provided by Zibo Wanjie Pharmaceutical Co., Ltd. was conducted under fasting and postprandial administration conditions to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation Telmisartan Amlodipine Tablets (specification: 80mg/5mg) and the reference preparation Telmisartan Amlodipine Tablets (trade name: Twynsta®, specification: 80mg/5mg) in healthy subjects.

To investigate the pharmacodynamic characteristics of orlistat capsules taken with meals, evaluate the pharmacodynamic differences between the two preparations after multiple administrations, and evaluate whether the two preparations are bioequivalent.